HXN-1031 / Earendil Labs - LARVOL DELTA

Development of a novel anti-CD19 x BCMA dual targeted T cell engager for the treatment of autoimmune diseases and B cell malignancies (EAACI 2026) - "Although CD19-targeted B cell depletion has demonstrated considerable therapeutic potential, its widespread use is limited by the pharmacokinetic (PK) limitations of BLINCYTO and the substantial expenses associated with CAR-T treatments. Conclusion HXN-1031 is a novel trispecific T cell engager with finely tuned activity, designed to reset immune homeostasis through the concurrent depletion of pathogenic B cells and plasma cells. These results highlight its strong potential as a therapeutic modality for a broad range of B cell- and plasma cell–driven autoimmune diseases and malignancies."

Immunology

Development of a novel anti-CD19 x BCMA dual targeted T cell engager for the treatment of autoimmune diseases and B cell malignancies (AAAAI 2026) - "In vivo, twice-weekly HXN-1031 demonstrated superior efficacy to Blinatumomab against CD19+ tumors, and significantly suppressed BCMA+ tumor growth, matching Teclistamab analogue efficacy. Conclusions HXN-1031 is an innovative TCE with finely tuned activity, designed to reset immune system by simultaneously depleting pathogenic B cells and plasma cells. It holds great potential in the treatment of various B cell and plasma cell related autoimmune diseases and malignancies."

Hematological Malignancies • Immunology • Oncology